HIV Enfeksiyonunun Güncel Tedavisi

Behice KURTARAN

doi:10.4274/mjima.2015.11

HIV Enfeksiyonunun Güncel Tedavisi

PDF

DERLEME

HIV Enfeksiyonunun Güncel Tedavisi

Mediterr J Infect Microb Antimicrob 2015;4:11-11 DOI: 10.4274/mjima.2015.11

PDF

İzin

Öz

Mevcut antiretroviral tedaviler ile insan immün yetmezlik virüsünün ‘Human immunodeficiency virus’ (HIV) eradikasyonu henüz mümkün olmamaktadır. Bu nedenle pek çok hastaya yaşam boyu tedavi uygulanmaktadır. Çeşitli epidemiyolojik çalışmalar düzenli ve sürekli tedavi ile, HIV ile enfekte bireylerin de normal yaşam beklentisine sahip olabileceğini göstermektedir. Tedavinin başarısını değerlendirmede virolojik, immünolojik ve klinik parametreler kullanılmaktadır. Viral yük, tedavi izleminin en önemli parametresidir. Günümüzde, özellikle daha önce tedavi almamış, başlangıç mutasyonu olmayan hastalarda tedavi başarısızlığı oldukça nadirdir. Mevcut tüm başlangıç kombinasyonları, iki nükleozit revers transkriptaz inhibitörü analoğunun nükleozit revers transkriptaz inhibitörleri, bir integraz inhibitörü, güçlendirilmiş proteaz inhibitörü veya non-nükleozit revers transkriptaz inhibitörü ile kullanılmasından oluşur. Bu derlemede HIV enfeksiyonu tedavisi güncel rehberler ışığında özetlenmiştir.

Anahtar Kelimeler: HIV enfeksiyonu, antiretroviral tedavi, nükleozit (t) revers transkriptaz inhibitörleri, non-nükleozit revers transkriptaz inhibitörleri, AIDS

Kaynakça

1

Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Sorensen HT, Gerstoft J. Impact of non-HIV and HIV risk factors on survival in HIVinfected patients on HAART: a population-based nationwide cohort study. PLoS One. 2011;6:e22698.

2

Hogg RS, Samji H, Cescon A, Modur S, Nepravnik S, Martin J, Gill J, Klein MB, Kirk G, Gange T. Temporal Changes in Life Expectancy of HIV+Individuals: North America. Abstract 137, 19th Conference on Retroviruses and Opportunistic Infections March 8 2012, Seattle. (http// www.retroconference.org/2012b/Abstracts/44961.htm).

3

Nakagawa F, Lodwick RK, Smith CJ, Cambiano V, Lundgren JD, Delpech V, Phillips AN. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26:335-43.

4

Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d’Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN; PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51-62.

5

Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, Quinzan G, Soavi L, Iannotti N, Malfatto E, Leone S. Ultrasensitive assessment of residual low-level HIV viremia in HAART- treated patients and risk of virological failure. J Acquir Immune Defic Syndr. 2012;60:473-82.

6

Maggiolo F, Migliorino M, Pirali A, Pravettoni G, Caprioli S, Suter F. Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment. J Acquir Immune Defic Syndr. 2000;25:36-43.

7

Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol. 1998;72:2422-8.

8

Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J Jr, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817-29.

9

Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, Eron JJ Jr. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011;204:515-20.

10

Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitorbased highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis. 2005;41:1326-32.

11

Phillips AN, Miller V, Sabin C, Cozzi Lepri A, Klauke S, Bickel M, Doerr HW, Hill A, Staszewski S. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS. 2001;15:2379-84.

12

Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD; EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-9.

13

Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JD; EuroSIDA study group. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 2007;370:407-13.

14

Lederman MM, McKinnis R, Kelleher D, Cutrell A, Mellors J, Neisler M, Cooney E, Haas DW, Haubrich R, Stanford J, Horton J, Landay A, Spreen W. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 2000;14:2635-42.

15

Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, Jung C, Mahamat A, Lang JM, Costagliola D. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004;18:2029-38.

16

Torti C, d’Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. BMC Infect Dis. 2011;11:23.

17

HIV 2012/2013. Editors: Hoffman C and Rockstroh JK. Medizin Fokus Verlag. Hamburg 2012. www.hivbook.com.

18

The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:808-22.

19

European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV-infected adults in Europe. October. 2015. http://www.eacsociety.org/files/2015_eacsguidelines_8_0-english_ rev-20160124.pdf.

20

HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Updated April 8, 2015. https://aidsinfo.nih.gov/guidelines/ html/1/adult-and-adolescent-arv-guidelines/1/panel-roster.

21

WHO Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015.

22

HIV/AIDS tanı tedavi rehberi. TC Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu. 2013 Ankara.

23

Berzow D. HIV-2 infection. “HIV 2015/2016” book. Editors: Hoffmann C ve Rockstroh JK. Hamburg, 2015;513-52.

24

www.ilacrehberi.com